Contineum Therapeutics Inc (CTNM) Stock Analysis
Verdict: AVOID
Peer trial fallout and steep cash burn shadow PIPE-791’s clinical potential, making CTNM a high-risk speculative trap.
Investment score: 36/100
Analysis as of
Is Contineum Therapeutics Inc stock worth reviewing? AI model thesis
Contineum Therapeutics crashed ~36% following mixed Phase 3 data from peer Bristol Myers Squibb regarding LPA1 receptor targeting. With $75.6M in cash offering roughly 16 months of runway and zero commercial revenue, the AI model views CTNM as an uncompelling risk profile until clinical efficacy is independently validated.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Contineum Therapeutics Inc opportunities and risks
What speaks for CTNM
- Strategic partnership and validation from Johnson & Johnson for PIPE-307
What speaks against CTNM
- Mechanistic cross-read failure across the LPA1 receptor inhibitor class
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CTNM | n/a | 0.0x | n/a | 0.0% | 0.0% | -16.6% |
| AVIR | n/a | 0.0x | n/a | 0.0% | 0.0% | -37.8% |
| RLMD | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.5% |
| PLTH.CN | n/a | 0.4x | n/a | 41.0% | -66.9% | -28.0% |
| TTRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.3% |
| EYPT | n/a | 99.8x | n/a | 41.8% | -10994.7% | -97.5% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.0% |
Frequently asked questions about Contineum Therapeutics Inc (CTNM)
Is CTNM stock a good investment?
The cached TradeMates AI model rates Contineum Therapeutics Inc as AVOID with an investment score of 36/100. Contineum Therapeutics crashed ~36% following mixed Phase 3 data from peer Bristol Myers Squibb regarding LPA1 receptor targeting. With $75.6M in cash offering roughly 16 months of runway and zero commercial revenue, the AI model views CTNM as an uncompelling risk profile until clinical efficacy is independently validated. This is algorithmic model output, not personal investment advice.
Is CTNM stock a buy?
The TradeMates model verdict for CTNM is AVOID with an investment score of 36/100. Treat this as a model signal to review, not a personal buy recommendation.